简单概括下来就是对50%病患有效，其中一半两周内出院，今晚美股要大涨了。

某国最先爆发疫情，最先拿到药，最先展开盲测，最后却因病人不够宣告此药无效，真的是一声叹息。

新闻出来了 大家都有自己解读，信不信都是自己的事儿。

有人信了买了股票赚一笔，有人不信在那酸葡萄酸莲花清，这都是个人的选择，列出再多的数据也没用，你说是不是？

这是Gilead自己发布的数据，之前好几个第三方trial也给出类似结果，当然不包括泄漏世卫数据的那家，后续更详细的数据马上会出来，FDA已经开始在程序上把瑞德西韦列为治疗新冠的专用药了。

我们应该为有有效药物的出现感到高兴，可是有些人看不得这些。幸好我们是在小坡，FDA批准后这边应该很快也会有了。

然后被WHO不知道哪位大人给mistakenly post 到WHO的网站。这怎么看也不是吉利德自己要泄漏的吧

In that 397-patient trial, Gilead said 62% of patients treated early with remdesivir were discharged from the hospital, compared with 49% of patients who were treated later in the course of the infection.　

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, said partial results from its 1,063-patient trial show that hospitalized COVID-19 patients given remdesivir recovered in 11 days, compared to 15 days for patients given a placebo.　

The study showed a trend toward better survival for remdesivir - 8% of patients given the drug died compared with 11.6% in the placebo group - but the difference was not statistically significant so may not be due to Gilead’s drug.